The Dow Jones today traded 80 points lower in pre-market trading as the Federal Reserve kicked off its quarterly Federal Open Market Committee meeting.
Markets anticipate that the Fed will hold off on raising interest rates until June.
While interest rates are likely to remain unchanged, investors are paying close attention to any changes in the rhetoric used to describe the state of the American economy.
by A.J. Bursick
Billionaire entrepreneur Mark Cuban invested in a small biotech company that will revolutionize the way doctors approach chest pains.
Of course, average investors don't have the ability to invest in such companies pre-IPO.
Between Oct. 5 and Nov. 11, one of the bellwether biotech exchange-traded funds fell 10.5%.
That's a correction, as defined by most market watchers.
And most investors – and their "enablers" on Wall Street – have shied away from biotech shares since. They're jittery.
In fact, I saw one august financial publication – the highly respected Investor's Business Daily – warn folks away from biotech in 2018 due to "median tenure of chief executives at large-cap biotech companies."
That's not just a stretch. It's a load of malarkey.
Here's the thing: If you want to double your money in 2018, you absolutely must invest in biotech.
That temporary dip in the iShares Nasdaq Biotechnology Index Fund ETF came after congressional Republicans ditched efforts to repeal and replace Obamacare. If there's one thing Wall Street hates, it's uncertainty.
As you might expect, Wall Street's panic led it to ignore some shares that have very bright futures – and are now trading at huge discounts.
So I've crunched the numbers – and done the research – and have identified three beaten-down biotech leaders that are poised to make huge comebacks throughout 2018.
I think you should put all three of these 2018 biotech comeback stocks on your "buy" list.
Especially the one that I believe will soar 110.5% in just 12 months...
The Dow Jones today is dropping thanks to more turmoil in Spain over Catalonian secession…
Dow Jones futures are down 85 points ahead of the opening bell as Spain's proposal to strip Catalonia's leaders of their authority tanked European stocks.
by Stephen Mack
Our latest list of stocks to watch now includes an auto company with a super luxury truck, an aerospace contractor honored by NASA, and a pharmaceutical company getting attention from Wall Street.
Check out the stocks that are shaking up Wall Street today.
by Stephen Mack
Here's a look at three new stocks to watch. A solar energy stock may be flying too close to the sun, a massive new private equity fund gets its feet wet, and a fallen biotech star may be ready for another breakout.
Back in October, I did something crazy.
That's when I told the paid-up members of my Radical Technology Profits trading service to buy a small-cap biotech stock.
Here's why that move was a bit nuts.
At the time, it looked like Hillary Clinton would soon enter in the White House and clamp down on drug prices – and so the biopharmaceutical sector was deeply out of favor.
Turns out, however, our crazy bet paid off.
Despite his campaign rhetoric, President Donald Trump has pulled back from his own fiery rhetoric about drug-price caps.
That helped pushed biotech and drug stocks into a big uptrend.
And my paid-up members made peak gains of 116% – in just over eight months.
Today, things have changed – and investing in biopharma stocks is generally seen as a smart move. However, that means a lot of these shares have been bid up, and your best move is to buy big winners at deep discounts.
But to do that, you have to know how to find those deals.
I do.
Today I'll show you how you can, too.
And I'll reveal the three best biotech bargains out there right now.
All three have triple-digit gains potential...
In Dow Jones news today, stock prices were flat as oil prices remain extremely volatile.
President Donald Trump also said today that he didn't have a tape of his conversations with former FBI Director James Comey.
by Alex McGuire
The pharma sector has widely outperformed the broader market lately.
That's why we've made this list of the 10 top pharmaceutical stocks to watch in May 2017.
We're also including our pick for one of the best pharma stocks to buy this year. Check it out...
As I've said before, buying a drugmaker with true billion-dollar "blockbuster" potential is like grabbing a license to print money.
Of course, it's always at least possible to grab these shares on their way up, but that's a little like fixing the barn door after the horses have bolted.
For the biggest possible pharma profits, investors have to look ahead into the firm's "pipeline," its arsenal of yet-to-be-released drugs that's critical to keeping a drug company competitive in the long term.
Today, I've got the perfect "Buy" recommendation for a company that's doing just that...
